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Abstract: With the growing interest in the use of nanoparticles (NPs) in nanomedicine, there is
a crucial need for imaging and targeted therapies to determine NP distribution in the body after
systemic administration, and to achieve strong accumulation in tumors with low background in other
tissues. Accumulation of NPs in tumors results from different mechanisms, and appears extremely
heterogeneous in mice models and rather limited in humans. Developing new tumor models in
mice, with their low spontaneous NP accumulation, is thus necessary for screening imaging probes
and for testing new targeting strategies. In the present work, accumulation of LipImageTM 815,
a non-specific nanosized fluorescent imaging agent, was compared in subcutaneous, orthotopic and
metastatic tumors of RM1 cells (murine prostate cancer cell line) by in vivo and ex vivo fluorescence
imaging techniques. LipImageTM 815 mainly accumulated in liver at 24 h but also in orthotopic
tumors. Limited accumulation occurred in subcutaneous tumors, and very low fluorescence was
detected in metastasis. Altogether, these different tumor models in mice offered a wide range of
NP accumulation levels, and a panel of in vivo models that may be useful to further challenge NP
targeting properties.
Keywords: prostate cancer; fluorescence imaging; bioluminescence imaging; fluorescence
tomography; enhanced permeability and retention (EPR) effect; LipImageTM
1. Introduction
New probes for tumor imaging and local therapies are an important clinical need. Currently,
clinical developments are mainly based on new radionuclides for positron emission tomography
(PET). However, there is growing interest in nanoparticles (NPs), because they offer various specific
properties, including high surface-to-volume ratio, high surface energy, and a wide range of additional
mechanical, thermal, electrical, magnetic, and optical properties [1–3]. NPs further offer possibilities to
combine several contrast agents for multimodal imaging, to be decorated with various biological and
chemical moieties and to cargo therapeutic agents.
Determining the distribution of nanocarriers within the body following systemic administration
in order to achieve high accumulation of NPs in tumors with low background in other tissues is the
major challenge for nanomedicine. NP characteristics have an impact on their pharmacokinetics [4,5],
and longer plasmatic half-life favors higher accumulation within the tumor. Such accumulation of NPs
in tumors results from different mechanisms, either specific or nonspecific, and involves different cell
populations, including cancer and stroma cells [6,7].
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The enhanced permeability and retention (EPR) effect [8,9] has been suggested to be the major
underlying mechanism of passive NP accumulation in tumors. The EPR effect, although efficient
in mice, appears to be extremely heterogeneous—or possibly totally ineffective—in humans [10,11],
resulting in low or no accumulation of NPs in human tumors. Since the EPR effect fails in the clinic,
new tumor models with low spontaneous NP accumulation are required to screen imaging probes and
to test new targeting strategies.
Fluorescent imaging on mice models is a convenient way to initiate the screening process of
NP-based imaging probes and to provide key information about NP properties. Although in vivo
fluorescence imaging does not discriminate between the different mechanisms involved in NP
accumulation in tumors, it allows for rapid evaluation of the overall targeting efficiency [12]. In order
to develop new tumor models in mice, the aim of the present work is to study NP accumulation
for a single tumor cell line according to different tumor locations. For this purpose, RM1, a murine
prostate cancer cell line, was used at different implantation sites to generate subcutaneous, orthotopic
and metastatic tumors. LipImageTM 815, a non-specific nanosized (80-nm diameter) fluorescent
imaging agent, was injected intravenously to compare NP accumulation in the various tumor locations
and types.
2. Results
2.1. In Vivo Imaging of LipImageTM 815 in Mice Bearing RM1-Subcutaneous Tumors
RM1-CMV/Fluc cells were injected subcutaneously (2 × 106 cells/100 µL) into the posterior right
leg of the mice (n = 3). One week after injection of cells, tumors were monitored by bioluminescence
imaging (BLI) (Figure 1A). LipImageTM 815 was then injected into the mice (14 × 1012 particles) via
the tail vein and could be monitored by live fluorescence imaging (Figure 1B and Video S1).
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(A) Bioluminescence image (BLI) of a representative mouse; (B) Fluorescence reflectance imaging 
(FRI) of a representative mouse at different time after LipImageTM 815 injection; (C) FRI of a 
representative mouse 6 h and 24 h after LipImageTM 815 injection, respectively; (D) Ex vivo BLI and 
FRI of mouse organs 24 h after LipImageTM 815 injection. 
The fluorescent signal was immediately detectable in vasculature, and within a few seconds in 
the kidney. Hyper-vascularization revealed by instant fluorescence reflectance imaging (FRI) was the 
first indication of the presence of a tumor on the right leg (Video S1). After 1 h, (Figure 1B), the 
fluorescent signal had accumulated in the liver and in the tumor. At 6 h and 24 h, both instant FRI 
(Figure 1B) and dark box FRI (Figure 1C) revealed a high fluorescent signal resulting from 
LipImageTM 815 accumulation in the subcutaneous tumors and in the liver, with limited background 
Figure 1. In vivo detection of LipImageTM 815 accumulation in subcutaneous tumors. (A) Bioluminescence
image (BLI) of a representative mouse; (B) Fluorescence reflectance imaging (FRI) of a representative mouse
at different time after LipImageTM 815 injection; (C) FRI of a representative mouse 6 h and 24 h after
LipImageTM 815 injection, respectively; (D) Ex vivo BLI and FRI of mouse organs 24 h after LipImageTM
815 injection.
The fluorescent signal was immediately detectable in vasculature, and within a few seconds in
the kidney. Hyper-vascularization revealed by instant fluorescence reflectance imaging (FRI) was
the first indication of the presence of a tumor on the right leg (Video S1). After 1 h, (Figure 1B), the
fluorescent signal had accumulated in the liver and in the tumor. At 6 h and 24 h, both instant FRI
(Figure 1B) and dark box FRI (Figure 1C) revealed a high fluorescent signal resulting from LipImageTM
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815 accumulation in the subcutaneous tumors and in the liver, with limited background fluorescence
in other tissues. As shown in Figure S1, LipImageTM 815 accumulation did not interfere with the
BLI signal, which increased as the tumor grew. Mice were euthanized 24 h after LipImageTM 815
injection, and organs were imaged by BLI and FRI (Figure 1D). BLI revealed the presence of tumor
cells exclusively in the tumor sample. Quantification of FRI signal for ex vivo samples is expressed
as photons·s−1·cm−2·sr−1. The highest fluorescent signal from LipImageTM 815 was found in the
liver (1.47 × 1010 ± 3.14 × 109 ph·s−1·cm−2·sr−1; n = 3). Lower levels were detected in the tumor
(4.55 × 109 ± 4.22 × 108 ph·s−1·cm−2·sr−1; n = 3), but also in the intestines, kidneys, lungs and spleen.
2.2. In Vivo Imaging of LipImageTM 815 in Mice Bearing RM1-Prostate Tumors
RM1-CMV/Fluc cells (5 × 105/10 µL per lobe) were injected into prostate lobes during open
surgery (n = 5). Tumor growth was monitored by BLI (Figure 2A). Four days after surgery, LipImageTM
815 was injected into the mice (14 × 1012 particles) via the tail vein, and the fluorescence signal
was followed by FRI and Fluorescence molecular tomography (FMT) 6 and 24 h after injection.
As shown in Figure 2B, FRI revealed a fluorescence signal on the ventral face in regions corresponding
to the location of the liver and prostate. FMT provided 3D images of the fluorescent signals in
the prostate (Figure 2C) and allowed quantification (Figure 2D). Mice were sacrificed 24 h after
LipImageTM 815 injection, and the excised prostates were immediately imaged by BLI (Figure 3A)
and FRI (Figure 3B). The fluorescent signal from LipImageTM 815 corresponded to the BLI signal
from RM1 cells. The fluorescence signal from LipImageTM 815 in the RM1 tumors was quantified
(1.65 × 1010 ± 4.22 × 108 ph·s−1·cm−2·sr−1; n = 5). Prostates were further processed for histology.
Hematoxylin-eosin-safran (HES) staining (Figure 3C) revealed cancer cells and NIR microscopy
(Figure 3D) revealed the presence of the NIR fluorophore.
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Figure 3. Ex vivo imaging and histology of LipImageTM 815 accumulation in prostate tumors. Prostates
were excised and imaged (A) by BLI and (B) by FRI; (C) HES coloration revealed tumor cells and (D)
epifluorescence revealed fluorescent signals from LipImageTM 815 in prostate cancer cryosection.
2.3. In Vivo Imaging of Metastasis with LipImageTM 815
Intra-cardiac echography-guided injection of RM1-CMV/Fluc cells (105/100 µL) in the left ventricle
(Video S2) resulted in metastatic dissemination. First metastasis was able to be detected by BLI as
soon as 7 days after cells injection (Figure S3; but in the present work, mice were assayed 13 days after
injection (Figure 4A,B) (n = 11). Six (Figure 4A; n = 6) and 24 h (Figure 4B; n = 5) after LipImageTM 815
intravenous injection, the main fluorescence location detected was in the liver, but other locations were
also detected without a consistent fit with BLI metastasis location (Figure 4A,B, 1st column).
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5: heart, 6: intestines, 7: lungs, 8: stomach, 9: liver, 10: posteri r l gs, 11: anterior legs.
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Mice were sacrificed 6 or 24 h after LipImageTM 815 injection. The peritoneal cavity was opened
and the skin was removed before BLI and FRI. Again, the liver remained the most fluorescent organ
detected (Figure 4A,B, 2nd column). Organs and regions exhibiting a BLI signal were dissected
and imaged for BLI and FRI (Figure 4A,B, columns 3–5). Apart from the legs (bone metastasis),
the fluorescent signal of NPs did not match the metastatic locations as revealed by BLI. As shown
on Figure 5, organs such as the liver and kidneys exhibited high background fluorescence signals
throughout the entire organ, and did not exhibit enhancement related to the location of cancer cells.
For other organs, such as the stomach or testicles, the fluorescence background was low, and hot
spots of fluorescent signal perfectly fitted with metastatic locations revealed by BLI. Nevertheless,
the fluorescence level in metastasis remained low, irrespective of location, nearing the background
level at 2.31 × 109 ± 1.44 × 109 ph·s−1·cm−2·sr−1 (n = 11).
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Figure 5. Ex vivo imaging of LipImageTM 815 accumulation in organs containing metastasis. BLI
revealed the tumor location and FRI revealed LipImageTM 815 accumulation 6 h or 24 h after
intravenous injection. In the kidneys and liver, LipImageTM 815 resulted in a disperse fluorescence
signal without detectable accumulation in the metastasis; while in the stomach and testicles,
fluorescence coincided with metastasis location. The FRI display scale is identical for all images.
2.4. Ex Vivo Quantification of LipImageTM 815 Accumulation in Tumors and Organs
Quantification of fluorescence signals in tumors and organs from mice bearing subcutaneous
tumors, orthotopic tumors, or metastasis was assessed by FRI ex vivo and the data plotted (Figure 6).
The highest fluorescence level from LipImageTM 815 at 24 h was found in healthy livers and orthotopic
tumors. The fluorescence level in orthotopic tumors was very high compared with subcutaneous
tumors, which was, in turn, higher than metastasis. The fluorescence level in metastasis was very low;
lower than the fluorescence level in healthy organs.
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3. Discussion
Using a single murine prostate cancer cell line (RM1), via different routes, to generate various types
of tumors (orthotopic, subcutaneous and metastatic), a constant dose of NPs and a wide panel of in vivo
and ex vivo fluorescence imaging techniques, we demonstrated here that the non-specific labeling
pattern varied according to tumor type. LipImageTM 815 accumulation was highly predominant in
orthotopic tumors when compared with subcutaneous tumors and disseminated metastasis.
RM1 is a mouse prostate cancer cell line syngenic in C57BL/6 mice [13]. It was genetically
modified to produce a constitutive Fluc reporter gene and to make in vivo detection by BLI possible,
even for small or deep tumors in mice. The BLI signal was not only used to follow tumor growth, but
also to compare BLI and fluorescence imaging patterns. As luciferase activity requires oxygen and
intraperitoneal injected luciferin (MW = 280 D) as a substrate, the BLI signal further confirms that the
tumors are not hypoxic, and are properly vascularized. RM1 tumors are very fast-growing, providing
significant orthotopic prostate tumors in 4 days, subcutaneous tumors in 7 days, and metastasis in
13 days. Thus, the present RM1 models provided a complete panel of different tumor types exhibiting
different levels of NP accumulation, making wide screening of NPs possible in a short period of time.
On the other hand, the rapid growth of RM1 tumors is not favorable for long term studies, as tumors
rapidly reached ethical endpoints. Finally, as RM1 is syngenic in C57BL/6 mice, the tumors grew in a
microenvironment more representative of the clinical physio-pathological context. The rapid growth
of RM1 tumors is a convenient feature for experimental purposes, but clearly diverges from a human
tumor growth rate that may influence tumor properties. In the current work, however, the level of NP
accumulation in RM1 tumors is not correlated with growing time.
Present data showed that the level of NP accumulation in a tumor was not a characteristic of the
tumor cells, but involved other parameters, including tumor location. As a limitation of the present
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study, the different tumor locations required different implantation methods, which may influence NP
accumulation. For metastasis, however, the fluorescence level is low, irrespective of location.
The fluorescent signal in tumors may result from several mechanisms, including retention
in extracellular space, binding to or internalization in tumor cells, and tumor microenvironment
components [6,7]. Variations in NP accumulation in tumors are often attributed to variations in EPR
effect. The EPR effect results from hyper-permeability of the tumor blood vessels and dysfunction
of intra-tumoral lymphatics drainage; the first mechanism enables nanoparticles to enter the tumor
interstitial space, while the second one allows particles to stay in the tumor for a longer time [14].
In the present work, solid evidence that accumulation results from a true EPR effect is lacking.
Vascularization is a key parameter for NP accumulation in different tumors types; but in the present
work, no information—such as pericytes coverage or fenestration sizes—is available. Regardless
of the mechanism involved, our results confirmed that the resulting non-specific accumulation of
NPs in tumors is highly variable. Conversely, accumulation found in some other normal tissues
demonstrates that these mechanisms are no more efficient within metastasis or subcutaneous tumors
than in healthy tissues.
LipImageTM 815 NPs (50 nm) have previously been characterized for their optical and
pharmacokinetic characteristics [15], and have been shown to display a long shelf life, as well as
colloidal and optical stabilities, with high brightness and strong and long accumulation in subcutaneous
tumors in mice [15]. Injection of these NPs in immunodeficient Swiss nude mice with implanted human
prostate cancer PC3 resulted in strong and long-term fluorescent labeling of the tumor [15], but data are
lacking concerning NP stability. LipImageTM 815 NPs (80 nm) also accumulated in RM1 subcutaneous
tumors at 24 h, but their long-term residence could not be confirmed, as tumors grew very quickly,
requiring rapid euthanasia of the mice. The post-mortem analysis of individual organs excised 24 h
post NP injection showed high accumulation in the liver, but the fluorescent signal in the tumor was
about 4 times less, and was not clearly different from those in organs such as the kidneys, intestines or
spleen. As subcutaneous tumors grew on the surface, fluorescence from NP accumulation was easily
detected, and changes in the fluorescence signal could be quantified. That makes this model quite
attractive, as small chemical modifications in NPs induced changes in NP accumulation in the tumor
that could be easily monitored by FRI [12].
RM1 orthotopic tumors are deep in the body and thus detection of the fluorescence signal was
impaired by photon absorption by the tissues. However, a deep tumor location is more favorable
for fluorescence tomography, and FMT allowed for fluorescence detection and absolute in-depth
quantification. Both in vivo and ex vivo imaging methods confirmed high levels of accumulation
of LipImageTM 815 in RM1 orthotopic tumors. Because they grow in an original microenvironment,
orthotopic tumors are relevant from a physio-pathological point of view; but, as they exhibit a high
level of passive NP accumulation, they behave quite differently from the clinical context.
LipImageTM 815 accumulation in disseminated metastasis is low at 24 h. Combined with
in-depth localization, the fluorescence signal is not detectable by in vivo fluorescence imaging. Tumor
localization is made possible by BLI, and a fluorescence signal is detectable by ex vivo FRI only in
organs with low background. The low level of LipImageTM 815 accumulation in RM1 metastasis may
be relevant for screening new strategies dedicated to circumventing EPR failures currently reported in
a clinical context [16].
The choice of animal model necessary for rapid and extensive evaluation of NPs requires
improvement towards a more clinically-relevant model for imaging probe evaluation. As illustrated
by this study using LipImageTM 815, even when using a single NP and a single cell line, non-specific
accumulation clearly depends on a lot of factors, including tumor type and location. Other factors, such
as tumor size, injection routes, doses and injection scheme, may further influence NP accumulation.
Although it is not wholly representative of the clinical context, each tumor type may be useful for
challenging NP properties.
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4. Materials and Methods
4.1. Animal Handling and Tumor Generation
Animal manipulations, approved by the local ethical committee (CEEA 50) under agreement
A50120196, were performed in agreement with French and European directives on the care and use of
animals. B6 Albino (B6N-Tyrc−Brd/BrdCrCrl) mice (6- to 8-weeks-old) were maintained in standard
conditions under a 12-h light/dark cycle with water and food provided ad libitum at the University
of Bordeaux animal facilities. Manipulations were performed on anesthetized animals using 2%
isoflurane (Belamont, Nicholas Piramal Limited, London, UK) in air.
Orthotopic tumors were induced by cell injection within the prostate on anesthetized mice.
The skin and the abdominal muscles were incised by a short section and the seminal glands were
pulled back outside the body. Cells (5 × 105/10 µL per lobe) were injected in the two dorsal prostate
lobes and the seminal glands returned to the abdomen. The incision was then closed with sutures.
Metastasis was induced by intra-cardiac cell injection (1 × 105/100 µL) in the left ventricle with
ultrasound guidance on anesthetized mice. Subcutaneous tumors were generated by cell injection
(2 × 106/100 µL) in the posterior right leg. Before the imaging session, regions to be imaged were
shaved with clippers and depilatory cream. LipImageTM 815 (31.5 µM of NIR fluorophore) were
injected via the tail vein. After in vivo imaging, organs were removed from euthanized mice and
placed in cold phosphate-buffered saline (PBS) in a petri dish and imaged ex vivo.
4.2. LipImageTM 815 Synthesis and Characterization
The IR780-lipid dye was first synthetized [15]. An oil premix with, respectively, 85, 255, and 65 mg
of oil, Suppocire NB™ (Gattefosse S.A., Saint-Priest, France) and lecithin was prepared. IR780-lipid dye
solution (10 mg/mL; 200 µL) in ethanol was poured into a 5-mL vial and mixed with the oil premix
melted at 50 ◦C. The mixture was homogenized and the solvent was then evaporated under argon flux.
After homogenization at 50 ◦C, the continuous aqueous phase, composed of 345 mg of MyrjTM S40
(Croda Uniquema; Chocques, France) and the appropriate amount of aqueous solution (154 mM NaCl
qs 2 mL), was introduced. The mixture was placed in a water bath at 50 ◦C and was then sonicated
for 5 min using a VCX750 Ultrasonic processor (power output 190 W, 3-mm probe diameter, Sonics).
LipImageTM 815 solution was dialyzed against 1000 times their volume in the appropriate aqueous
buffer overnight at room temperature (12 to 14,000 Da MW cut off membranes, ZelluTrans, Carl Roth,
France). The nanoparticle dispersion was finally sterilized by filtration through a 0.22 µm Millipore
membrane. Size distribution of LipImage™ 815 was measured with a Zetasizer (Nano ZS, Malvern
instrument, Worcestershire, UK) (Figure S2). The number of particles was calculated by dividing the total
volume of lipids (total mass of oil, wax, lecithin and PEG assuming an overall density of 1.05 g·cm−3)
divided by the individual volume of LipImageTM 815 nanoparticles (size = 74.4 nm; Figure S2).
4.3. Cell Line Generation and Culture
Murine prostate cancer cell line RM1, initially obtained from Dr. T.C. Thompson (Baylor
College of Medicine, Houston, TX, USA), was genetically engineered for constitutive expression
of firefly luciferase (RM1-CMV/Fluc) as previously described [12], and was maintained in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(Invitrogen), 1% antimycotic-antibiotic mix (PSA, Invitrogen) and blasticidin (10 µg/mL, Euromedex,
Souffelweyersheim, France). Cell line was maintained in a humidified 5% CO2 incubator at 37 ◦C.
4.4. Bioluminescence Imaging (BLI)
BLI was performed at Vivoptic (UMS 3767—Univ. Bordeaux) using Lumina LT (Perkin Elmer Inc.,
Boston, MA, USA). Mice received an intra-peritoneal injection of D-luciferin (2.9 mg in 100 µL PBS,
Promega, Madison, WI, USA), and were anesthetized 5 min later. Bioluminescence images (1 min,
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4 × 4 binning) and photographs (100 ms) were acquired successively 8 min after D-luciferin injection.
Images acquisition and analysis were performed using Living Image software.
4.5. Fluorescence Reflectance Imaging (FRI)
FRI was performed using the Lumina LT apparatus (Perkin Elmer, Boston, MA, USA) with the
745 nm excitation filter and the 810–875 nm emission filter. Fluorescence images (1 s, 4 × 4 binning)
and photographs (100 ms) were acquired successively, and analyzed using Living Image software. FRI
signal is expressed as photons·s−1·cm−2·sr−1.
FRI was also performed using the per-operatory camera system Fluobeam® (Fluoptics, Grenoble,
France) at a spectral window of excitation of 780 nm and with an emission of 820 nm. The image was
analyzed using Image J software.
4.6. Fluorescence Molecular Tomography (FMT)
Mice were imaged in a Fluorescence Molecular Tomograph (FMT®) 4000 (Perkin Elmer, Boston,
MA, USA). Scanning was performed using the 745 channel, and the fluorescence signal was filtered
with the 770–800 nm filter emission. The images were reconstructed and analyzed using the
TrueQuant software.
4.7. Histology and Microscopic Imaging
Tumors were frozen and stored at −80 ◦C. Tumor slices (10 µm) were obtained, fixed with 4%
paraformaldehyde (10 min, room temperature), and hematoxylin-eosin-safran staining was performed.
LipImageTM 815 fluorescence detection was performed using Leica DM 5500 microscope fitted with
pE-100 (Ex 770 nm) Cool LED and a indocyanine (775/845 nm) filter (Leica Microsystems, Wetzlar,
Germany).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2584/s1.
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